Literature DB >> 23372359

Role of surgical resection for multiple hepatocellular carcinomas.

Sung Hoon Choi1, Gi Hong Choi, Seung Up Kim, Jun Yong Park, Dong Jin Joo, Man Ki Ju, Myoung Soo Kim, Jin Sub Choi, Kwang Hyub Han, Soon Il Kim.   

Abstract

AIM: To clarify the role of surgical resection for multiple hepatocellular carcinomas (HCCs) compared to transarterial chemoembolization (TACE) and liver transplantation (LT).
METHODS: Among the HCC patients who were managed at Yonsei University Health System between January 2003 and December 2008, 160 patients who met the following criteria were retrospectively enrolled: (1) two or three radiologically diagnosed HCCs; (2) no radiologic vascular invasion; (3) Child-Pugh class A; (4) main tumor smaller than 5 cm in diameter; and (5) platelet count greater than 50 000/mm(3). Long-term outcomes were compared among the following three treatment modalities: surgical resection or combined radiofrequency ablation (RFA) (n = 36), TACE (n = 107), and LT (n = 17). The survival curves were computed using the Kaplan-Meier method and compared with a log-rank test. To identify the patients who gained a survival benefit from surgical resection, we also investigated prognostic factors for survival following surgical resection. Multivariate analyses of the prognostic factors for survival were performed using the Cox proportional hazard model.
RESULTS: The overall survival (OS) rate was significantly higher in the surgical resection group than in the TACE group (48.1% vs 28.9% at 5 years, P < 0.005). LT had the best OS rate, which was better than that of the surgical resection group, although the difference was not statistically significant (80.2% vs 48.1% at 5 years, P = 0.447). The disease-free survival rates were also significantly higher in the LT group than in the surgical resection group (88.2% vs 11.2% at 5 years, P < 0.001). Liver cirrhosis was the only significant prognostic factor for poor OS after surgical resection. Clinical liver cirrhosis rates were 55.6% (20/36) in the resection group and 93.5% (100/107) in the TACE group. There were 19 major and 17 minor resections. En bloc resection was performed in 23 patients, multi-site resection was performed in 5 patients, and combined resection with RFA was performed in 8 patients. In the TACE group, only 34 patients (31.8%) were recorded as having complete remission after primary TACE. Seventy-two patients (67.3%) were retreated with repeated TACE combined with other therapies. In patients who underwent surgical resection, the 16 patients who did not have cirrhosis had higher 5-year OS and disease-free survival rates than the 20 patients who had cirrhosis (80.8% vs 25.5% 5-year OS rate, P = 0.006; 22.2% vs 0% 5-year disease-free survival rate, P = 0.048). Surgical resection in the 20 patients who had cirrhosis did not provide any survival benefit when compared with TACE (25.5% vs 24.7% 5-year OS rate, P = 0.225). Twenty-nine of the 36 patients who underwent surgical resection experienced recurrence. Of the patients with cirrhosis, 80% (16/20) were within the Milan criteria at the time of recurrence after resection.
CONCLUSION: Among patients with two or three HCCs, no radiologic vascular invasion, and tumor diameters ≤ 5 cm, surgical resection is recommended only in those without cirrhosis.

Entities:  

Keywords:  Chemoembolization; Cirrhosis; Hepatectomy; Hepatocellular carcinoma; Liver transplantation

Mesh:

Year:  2013        PMID: 23372359      PMCID: PMC3554821          DOI: 10.3748/wjg.v19.i3.366

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  39 in total

1.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

2.  Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan.

Authors:  S Arii; Y Yamaoka; S Futagawa; K Inoue; K Kobayashi; M Kojiro; M Makuuchi; Y Nakamura; K Okita; R Yamada
Journal:  Hepatology       Date:  2000-12       Impact factor: 17.425

3.  Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation.

Authors:  Ronnie Tung-Ping Poon; Sheung Tat Fan; Chung Mau Lo; Chi Leung Liu; John Wong
Journal:  Ann Surg       Date:  2002-03       Impact factor: 12.969

4.  Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation.

Authors:  J M Llovet; J Fuster; J Bruix
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

5.  Surgical treatment of hepatocellular carcinoma in cirrhosis.

Authors:  R Dalla Valle; D Borie; L Hannoun; G C Botta
Journal:  Dig Liver Dis       Date:  2000-05       Impact factor: 4.088

6.  Simplified staging for hepatocellular carcinoma.

Authors:  Jean-Nicolas Vauthey; Gregory Y Lauwers; Nestor F Esnaola; Kim-Anh Do; Jacques Belghiti; Nadeem Mirza; Steven A Curley; Lee M Ellis; Jean-Marc Regimbeau; Asif Rashid; Karen R Cleary; David M Nagorney
Journal:  J Clin Oncol       Date:  2002-03-15       Impact factor: 44.544

7.  Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation.

Authors:  Charles H Cha; Leyo Ruo; Yuman Fong; William R Jarnagin; Jinru Shia; Leslie H Blumgart; Ronald P DeMatteo
Journal:  Ann Surg       Date:  2003-09       Impact factor: 12.969

8.  Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome.

Authors:  Ivo W Graziadei; Heiko Sandmueller; Peter Waldenberger; Alfred Koenigsrainer; Karin Nachbaur; Werner Jaschke; Raimund Margreiter; Wolfgang Vogel
Journal:  Liver Transpl       Date:  2003-06       Impact factor: 5.799

9.  Comparison of clinicopathologic characteristics and outcomes after resection in patients with hepatocellular carcinoma treated in the United States, France, and Japan.

Authors:  Nestor F Esnaola; Nadeem Mirza; Gregory Y Lauwers; Iwao Ikai; Jean-Marc Regimbeau; Jacques Belghiti; Yoshio Yamaoka; Steven A Curley; Lee M Ellis; David M Nagorney; Jean-Nicolas Vauthey
Journal:  Ann Surg       Date:  2003-11       Impact factor: 12.969

10.  Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy?

Authors:  René Adam; Daniel Azoulay; Denis Castaing; Rony Eshkenazy; Gérard Pascal; Kentaro Hashizume; Didier Samuel; Henri Bismuth
Journal:  Ann Surg       Date:  2003-10       Impact factor: 12.969

View more
  16 in total

1.  Number of nodules, Child-Pugh status, margin positivity, and microvascular invasion, but not tumor size, are prognostic factors of survival after liver resection for multifocal hepatocellular carcinoma.

Authors:  Brian K P Goh; Pierce K H Chow; Jin-Yao Teo; Jen-San Wong; Chung-Yip Chan; Peng-Chung Cheow; Alexander Y F Chung; London L P J Ooi
Journal:  J Gastrointest Surg       Date:  2014-05-23       Impact factor: 3.452

Review 2.  Diagnosis and treatment of hepatocellular carcinoma: An update.

Authors:  Javier Tejeda-Maldonado; Ignacio García-Juárez; Jonathan Aguirre-Valadez; Adrián González-Aguirre; Mario Vilatobá-Chapa; Alejandra Armengol-Alonso; Francisco Escobar-Penagos; Aldo Torre; Juan Francisco Sánchez-Ávila; Diego Luis Carrillo-Pérez
Journal:  World J Hepatol       Date:  2015-03-27

Review 3.  Surgical treatment of hepatocellular carcinoma: should resection be performed according to Barcelona Clinic Liver Cancer classification?

Authors:  Josep Fuster
Journal:  Hepat Oncol       Date:  2015-07-30

4.  Hepatic resection associated with good survival for selected patients with multinodular hepatocellular carcinoma.

Authors:  Jian-Hong Zhong; Fei-Xiang Wu; Hang Li
Journal:  Tumour Biol       Date:  2014-09-09

Review 5.  Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients.

Authors:  Antonio Facciorusso; Raffaele Licinio; Nicola Muscatiello; Alfredo Di Leo; Michele Barone
Journal:  World J Hepatol       Date:  2015-08-08

6.  Surgery for Intermediate and Advanced Hepatocellular Carcinoma: A Consensus Report from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014).

Authors:  Ming-Chih Ho; Kiyoshi Hasegawa; Xiao-Ping Chen; Hiroaki Nagano; Young-Joo Lee; Gar-Yang Chau; Jian Zhou; Chih-Chi Wang; Young Rok Choi; Ronnie Tung-Ping Poon; Norihiro Kokudo
Journal:  Liver Cancer       Date:  2016-09-14       Impact factor: 11.740

Review 7.  Hepatocellular Carcinoma in Liver Cirrhosis: Surgical Resection versus Transarterial Chemoembolization-A Meta-Analysis.

Authors:  Teodor Kapitanov; Ulf P Neumann; Maximilian Schmeding
Journal:  Gastroenterol Res Pract       Date:  2015-01-06       Impact factor: 2.260

8.  Reduced red blood cell count predicts poor survival after surgery in patients with primary liver cancer.

Authors:  Xiaomeng Xie; Mingjie Yao; Xiangmei Chen; Weiquan Lu; Quanjun Lv; Kaijuan Wang; Ling Zhang; Fengmin Lu
Journal:  Medicine (Baltimore)       Date:  2015-02       Impact factor: 1.889

Review 9.  Hepatic resection versus transarterial chemoembolization for the initial treatment of hepatocellular carcinoma: A systematic review and meta-analysis.

Authors:  Xingshun Qi; Diya Wang; Chunping Su; Hongyu Li; Xiaozhong Guo
Journal:  Oncotarget       Date:  2015-07-30

10.  Huge hepatocellular carcinoma with multiple intrahepatic metastases: An aggressive multimodal treatment.

Authors:  Satoshi Yasuda; Takeo Nomi; Daisuke Hokuto; Ichiro Yamato; Shinsaku Obara; Takatsugu Yamada; Hiromichi Kanehiro; Yoshiyuki Nakajima
Journal:  Int J Surg Case Rep       Date:  2015-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.